Compare ADUS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | OGN |
|---|---|---|
| Founded | 1979 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2009 | 2020 |
| Metric | ADUS | OGN |
|---|---|---|
| Price | $104.64 | $13.54 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 5 |
| Target Price | ★ $133.78 | $11.40 |
| AVG Volume (30 Days) | 226.0K | ★ 2.3M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ 23.40 | N/A |
| EPS | ★ 1.36 | 0.55 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | $9.17 | $0.45 |
| Revenue Next Year | $4.70 | $1.67 |
| P/E Ratio | $77.33 | ★ $24.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $87.95 | $5.69 |
| 52 Week High | $124.44 | $13.60 |
| Indicator | ADUS | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 77.90 | 72.77 |
| Support Level | $101.29 | $10.05 |
| Resistance Level | $112.98 | N/A |
| Average True Range (ATR) | 2.61 | 0.06 |
| MACD | 1.13 | -0.05 |
| Stochastic Oscillator | 96.04 | 76.19 |
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.